Search
Now showing items 11-13 of 13
Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
(ELSEVIER, 2022-09-01)
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of ...
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
(2022-01-24)
<h4>Background</h4>Patients with thoracic malignancies are at increased risk for mortality from Coronavirus disease 2019 (COVID-19) and large number of intertwined prognostic variables have been identified so far.<h4>Met ...
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
(2022-02-03)
<h4>Background</h4>In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural ...